Product Theater: Novo Nordisk - Data that Drives Decisions: GLP-1 RA for T2D Across CV and Renal Outcomes
Wednesday, December 9, 2026, – (America/New_York)
Product Theater
Recognize the importance of addressing increased cardiovascular (CV) and renal risk in adult patients with type 2 diabetes (T2D) with chronic kidney disease (CKD) and/or cardiovascular disease (CVD) and review guideline recommendations for managing these patient populations. Explore findings from a trial which evaluated the impact of a therapy on cardiorenal outcomes in adult patients with T2D and CKD. The audience will then have the opportunity to explore an additional outcomes trial in the CVD and T2D space.
Ozempic Injection Prescribing Information
Ozempic Pill Prescribing Information
Speakers
-
CRNP, CDCES